Scholar Rock Holding Corp(SRRK) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -3.45 | Insider Own | 17.26% | Shs Outstand | 121.6M | Perf Week | 2.88% |
| Market Cap | 5.23B | Forward P/E | - | EPS next Y | 21.73% | Insider Trans | 1.31% | Shs Float | 100.8M | Perf Month | -8.33% |
| Enterprise Value | 4.94B | PEG | - | EPS next Q | -0.85 | Inst Own | 101.08% | Short Float | 22.01% | Perf Quarter | -10.21% |
| Income | -0.41B | P/S | - | EPS this Y | -1.37% | Inst Trans | 4.36% | Short Ratio | 13.36 | Perf Half Y | -7.68% |
| Sales | 0.00B | P/B | 20.56 | EPS next 5Y | 27.07% | ROA | -94.63% | Short Interest | 22.18M | Perf YTD | -2.59% |
| Book/sh | 2.09 | P/C | 10.62 | EPS past 3/5Y | -13.45% -3.21% | ROE | -167.77% | 52W High | -30.52% ($61.76) | Perf Year | 44.87% |
| Cash/sh | 4.04 | P/FCF | - | Sales past 3/5Y | - | ROIC | -90.54% | 52W Low | 58.51% ($27.07) | Perf 3Y | 242.18% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -14.4% | Gross Margin | - | Volatility(W/M) | 4.1% 4.39% | Perf 5Y | 54.41% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1.9 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 7.02 | EPS Q/Q | 13.82% | Profit Margin | - | RSI (14) | 45.31 | Recom | 1.11 |
| Dividend Gr. 3/5Y | - | Current Ratio | 7.02 | Sales Q/Q | - | SMA20 | 2.39% ($41.91) | Beta | 0.79 | Target Price | $69.12 |
| Payout | - | Debt/Eq | 0.8 | Earnings | 2026/11/10 | SMA50 | -10.97% ($48.2) | Rel Volume | 0.56 | Prev Close | $43.9 |
| Employees | 289 | LT Debt/Eq | 0.78 | EPS/Sales Surpr. | 0.06% - | SMA200 | -10.95% ($48.19) | Avg Volume(3M) | 1.66M | Price | $42.91 |
| IPO | 2018/5/24 | Option/Short | Yes/Yes | Trades | 11011 | Volume | 932,077 | Change | -2.26% |
🧬 This is a late-stage clinical biotech company developing muscle-targeting therapeutics. Its lead candidate for spinal muscular atrophy (SMA), a rare muscle disease, has succeeded in late-stage clinical trials and is approaching regulatory approval. The company is also expanding into obesity treatment, where its therapies may help preserve muscle mass, broadening its presence in the healthcare space. The company's value hinges on the approval and launch of its key candidate.
Over the past 1 year, roughly in the middle
31% below its 1-year high.
Traded less than usual. That is 56% of its average volume.
Next earnings report: November 10
7 days to go.
SRRK has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -1.4% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +54.4%. The S&P 500 did +63% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
22.0% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #48 of 597 in the industry
Based on market cap of $5B.
CGON#46 Cg Oncology Inc $5B PER - 
MANE#47 Veradermics Inc $5B PER - SRRK#48 Scholar Rock Holding Corp $5B PER - 
COGT#49 Cogent Biosciences Inc $5B PER - 
PTCT#50 PTC Therapeutics Inc $5B PER - 
FAQ
What kind of company is SRRK?
SRRK belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of SRRK?
The market cap of SRRK is approximately $5.2B, ranking 1,345 within its sector.
What is the 52-week high and low for SRRK?
SRRK has recorded a 52-week high of $61.76 and a low of $27.07.
